Privigen is proven safe and effective for the treatment of PI, CIDP, and chronic ITP

Clinical trial results in patients with:

CIDP

Chronic ITP

PROVEN PROTECTION through reliable Ig replacement

In the US pivotal phase III trial (n=80)³
- The annual rate^§ of serious bacterial infections* (SBI) was 0.08 and of other infections was 3.55
- 97% of adverse reactions were non-serious, and 90% were rated mild or moderate in severity

In patients studied up to 29 months in the extension trial (n=55)²
- The annual rate^§ of SBI* was 0.02 and of other infections was 1.60
- 96% of adverse reactions were non-serious, and 93% were rated mild or moderate in severity

In the clinical studies, the most common adverse reactions, observed in >5% of study subjects, were headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.

*SBI were defined as pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

† Serious adverse reactions in the pivotal trial included hypersensitivity, chills, fatigue, dizziness, and increased body temperature (all severe), occurring in one subject and resulting in the subject’s withdrawal from the study. Two other subjects withdrew from the study due to adverse reactions of vomiting in one subject and chills and headache in the other.

‡11 patients had serious reactions in the extension trial.

§Infections per subject year.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit medical affairs

RAPID IMPROVEMENTS in functional ability*

*Almost all patients who responded to Privigen did so
after 1–2 maintenance treatments at Weeks 4 and 7.

Couple holding hands with Privigen vial imagery

Largest Ig Study in CIDP

PATH, one of two clinical trials,^† was the largest ever Ig study in CIDP, evaluating 207 patients

In the clinical studies, the most common reactions, observed in >5% of subjects, were headache, asthenia, hypertension, nausea, pain in extremity, hemolysis, influenza-like illness, leukopenia, and rash. A serious adverse reaction was hemolysis.

Privigen response rates among responders graph

Privigen improved strength in addition to functional ability

In PRIMA:

Privigen improved muscle strength as measured by Medical Research Council (MRC) sum score
- Average improvement in MRC sum score was 6.9 points
- A clinically meaningful improvement is defined as ≥3 points
Dominant hand grip strength improved by a mean of 14.1 kPa
- Similar results were observed in the nondominant hand

In PATH:

Privigen improved muscle strength as measured by MRC sum score
- Average improvement in MRC sum score was 3.6 points
- A clinically meaningful improvement is defined as ≥3 points
Dominant hand grip strength improved by a mean of 12.2 kPa
- Similar results were observed in the nondominant hand

†In a prospective, open-label, single-arm, multicenter clinical study (Privigen Impact on Mobility and Autonomy [PRIMA]), 28 subjects with CIDP received a Privigen loading dose of 2 g/kg followed by Privigen maintenance doses of 1 g/kg every 3 weeks for up to 21 weeks with 3-week follow-up. In a second prospective, open-label Privigen prerandomization phase of a multicenter clinical study (Polyneuropathy and Treatment with Hizentra [PATH]), 207 IVIg-pretreated subjects with CIDP received a Privigen loading dose of 2 g/kg followed by up to 4 Privigen maintenance doses of 1 g/kg every 3 weeks for up to 13 weeks.

‡Overall response rate was defined as percentage of subjects who experienced at least a 1-point decrease in adjusted INCAT score.

§Serious adverse reactions included hemolysis (2), exacerbation of CIDP (2), acute rash, increased diastolic blood pressure, hypersensitivity, pulmonary embolism, respiratory failure, and migraine. A total of 4 patients discontinued treatment due to serious adverse reactions.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit medical affairs

PROVEN EFFICACY with long-lasting response

Efficacy and safety – PI Patient and Daughter Walking

Chronic ITP Patient and Wife Taking a Photograph

In the ITP clinical trial,* platelet counts rose rapidly—response was both quick and lasting

80.7% of subjects (46 of 57) responded to Privigen with a 150% rise in platelet count within 7 days from ≤20 x 10⁹/L to at least 50 x 10⁹/L¹
The mean platelet count increased from 13 x 10⁹/L to 52 x 10⁹/L in only 1 day, before the second infusion¹
The duration of response was at least 8.8 days in 75% of patients¹

Adverse events were generally mild or moderate¹
- In clinical trials, the most common adverse reactions, seen in >5% of subjects, were laboratory findings consistent with hemolysis, headache, elevated body temperature, anemia, nausea, and vomiting. Serious adverse reactions were hemolysis and aseptic meningitis syndrome.

* A prospective, open-label, single-arm study assessed the efficacy and safety of PRIVIGEN in 57 subjects with chronic ITP and a platelet count of ≤20 x 10^9/L. The Privigen dose was 1 g/kg given on 2 consecutive days (2 g/kg total dose). The primary endpoint was the percentage of subjects with an increase in platelet counts to ≥50 x 10^9/L within 7 days of the first infusion.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit medical affairs

See Privigen dosing and infusion information

Use the guide or dosing calculator to determine the right amount of Privigen for your patients

Go to the dosing calculator

Privigen is the first and only IVIg stabilized with proline

Find out what proline is and why it's in Privigen

Learn more about proline

References: 1. Data on file. Available from CSL Behring as DOF PVG-006. 2. National Institutes of Health: ClinicalTrials.gov. Safety and efficacy of intravenous immunoglobulin IgPro10 in patients with primary immunodeficiencies. https://clinicaltrials.gov/ct2/show/results/NCT00322556. Accessed January 22, 2025. 3. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144.

References: 1. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen^®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.

References: 1. Data on file. Available from CSL Behring as DOF PVG-003. 2. Leger, JM et al. on behalf of the PRIMA study investigators. Efficacy and safety of Privigen^® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study ). Journal of the Peripheral Nervous System. 2013;18(3):130-140.